2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinChild, PreschoolDrug Therapy, CombinationFrailtyHemorrhageHumansMedicarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTreatment OutcomeUnited StatesConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claimsTrends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
Essa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal Of The American Heart Association 2023, 12: e028869. PMID: 37042289, PMCID: PMC10227267, DOI: 10.1161/jaha.122.028869.Peer-Reviewed Original Research
2021
Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Brindis R, Shen C, Yeh RW. Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovascular Interventions 2021, 14: 1386-1388. PMID: 34167685, PMCID: PMC8800637, DOI: 10.1016/j.jcin.2021.03.065.Peer-Reviewed Original ResearchMeSH KeywordsDrug Therapy, CombinationHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRegistriesTreatment OutcomeLack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation InhibitorsComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchMeSH KeywordsAgedDrug Therapy, CombinationFemaleHumansMaleMedicareMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStrokeTreatment OutcomeUnited StatesConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2020
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Faridi KF, Tamez H, Strom JB, Song Y, Butala NM, Shen C, Secemsky EA, Mauri L, Curtis JP, Gibson CM, Yeh RW. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation 2020, 142: 306-308. PMID: 32687440, PMCID: PMC7374757, DOI: 10.1161/circulationaha.120.047729.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicDual Anti-Platelet TherapyHumansMedicarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsThrombosisUnited StatesPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study